Diabetes mellitus and tuberculosis facts and controversies

Journal of Diabetes and Metabolic Disorders

Volumn 12, Issue 1, 2013, Pages

  Baghaei, Parvaneh ^a   Marjani, Majid ^a   Javanmard, Pedram ^b   Tabarsi, Payam ^a   Masjedi, Mohammad R ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b STONY BROOK UNIVERSITY   (United States)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic disease; Diabetes mellitus; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SULFONYLUREA; TUBERCULOSTATIC AGENT;

ADVERSE DRUG REACTION; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; LATENT TUBERCULOSIS; LIVER TOXICITY; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; RADIOGRAPHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SPUTUM CULTURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 84908109513     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-12-58     Document Type: Review

References (94)

1. Chang JT, Dou HY, Yen CL, Wu YH, Huang RM, Lin HJ, Su IJ, Shieh CC. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc 2011, 110(6):372-381.
2. Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis 2007, 45(4):436-438.
3. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, Van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health 2010, 15(11):1289-1299.
4. Webb EA, Hesseling AC, Schaaf HS, Gie RP, Lombard CJ, Spitaels A, Delport S, Marais BJ, Donald K, Hindmarsh P, Beyers N. High prevalence of mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc Lung Dis 2009, 13(7):868-874.
5. Ottmani SE, Murray MB, Jeon CY, Baker MA, Kapur A, Lonnroth K, Harries AD. Consultation meeting on tuberculosis and diabetes mellitus: meeting summary and recommendations. Int J Tuberc Lung Dis 2010, 14(12):1513-1517.
6. Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006, 100(5-6):415-431. Jul-Sep.
7. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163(9):1009-1021.
8. World Health Organization WHO report 2010 Geneva, Switzerland: Global tuberculosis control 2010, WHO/HTM/TB/2010.7. WHO; 2010, World Health Organization.
9. World Health Organization Tuberculosis country profiles 2010, http://www.who.int/tb/country/data/profiles/, World Health Organization.
10. Harries AD, Lin Y, Satyanarayana S, Lonnroth K, Li L, Wilson N, Chauhan LS, Zachariah R, Baker MA, Jeon CY, Murray MB, Maher D, Bygbjerg IC, Enarson DA, Billo NE, Kapur A. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. Int J Tuberc Lung Dis 2011, 15(11):1436-1444.
11. International Diabetes Federation IDF diabetes atlas 2009, Brussels, Belgium: International Diabetes Federation, 4, International Diabetes Federation.
12. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009, 9(12):737-746.
13. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010, 375(9712):408-418.
14. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, Safaie A, Forouzanfar M, Gregg EW. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National survey of risk factors for non-communicable diseases of Iran. Diabetes Care 2008, 31(1):96-98.
15. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010, 375(9728):1814-1829.
16. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
17. Goldhaber-Fiebert JD, Jeon CY, Cohen T, Murray MB. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiol 2011, 40(2):417-428.
18. Sidibe EH. Main complications of diabetes mellitus in Africa. Ann Med Interne (Paris) 2000, 151(8):624-628.
19. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997, 87(4):574-579.
20. Mansilla Bermejo MJ, Sanz Gil MJ, Moraleda Velasco P, Alvarez Prado A, Carbayo Garcia JJ, Mata Guijarro F. Tuberculin test in diabetic patients in a health center. Aten Primaria 1995, 16(3):154-157.
21. Vega RA, Conde JG, Diaz M. Prevalence of tuberculin reactivity and prevalence of risk factors for the development of active tuberculosis in a nursing home in Puerto Rico. P R Health Sci J 1996, 15(1):27-31.
22. Vega Torres RA, Conde JG, Diaz M. Prevalence of tuberculin reactivity and risk factors for the development of active tuberculosis upon admission to a nursing home. P R Health Sci J 1996, 15(4):275-277.
23. Nwabudike LC, Ionescu-Tirgoviste C. Intradermal reactions to purified protein derivative in patients with diabetes mellitus. Rom J Intern Med 2005, 43(1-2):127-132.
24. Hernandez Garcia P, Martinez Cruz F, Cayuelas Martinez T. PPD and chemoprophylaxis in diabetes mellitus. Aten Primaria 1992, 9(2):106-108.
25. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006, 7:56.
26. Chan-Yeung M, Cheung AH, Dai DL, Chan FH, Kam KM, Tam CM, Leung CC. Prevalence and determinants of positive tuberculin reactions of residents in old age homes in Hong Kong. Int J Tuberc Lung Dis 2006, 10(8):892-898.
27. Deshmukh PA, Shaw T. Pulmonary tuberculosis and diabetes mellitus. Ind J Tub 1984, 31:114-117.
28. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, Nelwan RH, Parwati I, van der Meer JW, Van Crevel R. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45(4):428-435.
29. Tatar D, Senol G, Alptekin S, Karakurum C, Aydin M, Coskunol I. Tuberculosis in diabetics: features in an endemic area. Jpn J Infect Dis 2009, 62(6):423-427.
30. Mugusi F, Swai AB, Alberti KG, McLarty DG. Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 1990, 71(4):271-276.
31. Basoglu OK, Bacakoglu F, Cok G, Sayiner A, Ates M. The oral glucose tolerance test in patients with respiratory infections. Monaldi Arch Chest Dis 1999, 54(4):307-310.
32. World Health Organization/International Union Against Tuberculosis and Lung Disease Collaborative framework for care and control of tuberculosis and diabetes Geneva, Switzerland, WHO; 2011, World Health Organization/International Union Against Tuberculosis and Lung Disease.
33. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5(7):e152.
34. Olmos P, Donoso J, Rojas N, Landeros P, Schurmann R, Retamal G, Meza M, Martinez C. Tuberculosis and diabetes mellitus: a longitudinal-retrospective study in a teaching hospital. Rev Med Chil 1989, 117(9):979-983.
35. Dobler CC, Flack JR, Marks GB. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open 2012, 2(1):e000666.
36. Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lonnroth K, Ottmani SE, Goonesekera S, Murray MB. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010, 15(11):1300-1314.
37. Boucot KR, Dillon ES, Cooper DA, Meier P, Richardson R. Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc 1952, 65(1:2):1-50.
38. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung GM, Law WS, Tam CM, Chan CK, Chang KC. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 2008, 167(12):1486-1494.
39. Young F, Critchley JA, Johnstone LK, Unwin NC. A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Global Health 2009, 5:9.
40. Alisjahbana B, Van Crevel R, Sahiratmadja E, Den Heijer M, Maya A, Istriana E, Danusantoso H, Ottenhoff TH, Nelwan RH, van der Meer JW. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis 2006, 10(6):696-700.
41. Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, Rojas R, Ferreyra-Reyes L, Cano-Arellano B, Bobadilla M, Small PM, Sifuentes-Osornio J. Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004, 27(7):1584-1590.
42. Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA, Osman MM. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 2006, 10(1):74-79.
43. Guptan ASA. Tuberculosis and diabetes: an appraisal. Ind J Tub 2000, 47:3-8.
44. Wang JY, Lee LN, Hsueh PR. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis 2005, 9(7):777-783.
45. Balde NM, Camara A, Camara LM, Diallo MM, Kake A, Bah-Sow OY. Associated tuberculosis and diabetes in Conakry, Guinea: prevalence and clinical characteristics. Int J Tuberc Lung Dis 2006, 10(9):1036-1040.
46. Al-Wabel AH, Teklu B, Mahfouz AA, Al-Ghamdi AS, El-Amin OB, Khan AS. Symptomatology and chest roentgenographic changes of pulmonary tuberculosis among diabetics. East Afr Med J 1997, 74(2):62-64.
47. Bacakoglu F, Basoglu OK, Cok G, Sayiner A, Ates M. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001, 68(6):595-600.
48. Park SW, Shin JW, Kim JY, Park IW, Choi BW, Choi JC, Kim YS. The effect of diabetic control status on the clinical features of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis 2012, 31(7):1305-1310.
49. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue chest service, 1987 to 1997. Chest 2001, 120(5):1514-1519.
50. Ocal S, Saka D, Ogretensoy M. Mild and severe forms of tuberculosis in diabetic and non-diabetic patients. J Diabetes 2009, 1(2):107-111.
51. Al-Tawfiq JA, Saadeh BM. Radiographic manifestations of culture-positive pulmonary tuberculosis: cavitary or non-cavitary?. Int J Tuberc Lung Dis 2009, 13(3):367-370.
52. Perez-Guzman C, Torres-Cruz A, Villarreal-Velarde H, Salazar-Lezama MA, Vargas MH. Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study. Int J Tuberc Lung Dis 2001, 5(5):455-461.
53. Umut S, Tosun GA, Yildirim N. Radiographic location of pulmonary tuberculosis in diabetic patients. Chest 1994, 106(1):326.
54. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, Van Crevel R. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010, 54(3):1068-1074.
55. Morris JT, Seaworth BJ, McAllister CK. Pulmonary tuberculosis in diabetics. Chest 1992, 102(2):539-541.
56. Weaver RA. Unusual radiographic presentation of pulmonary tuberculosis in diabetic patients. Am Rev Respir Dis 1974, 109(1):162-163.
57. Shaikh MA SR, Khan NB, Sharif NS, Saigh MO. Does diabetes alter the radiological presentation of pulmonary tuberculosis. Saudi Med J 2003, 24(3):278-281.
58. Baghaei P, Tabarsi P, Abrishami Z, Mirsaeidi M, Faghani YA, Mansouri SD, Masjedi MR. Comparison of pulmonary TB patients with and without diabetes mellitus type II. Tanaffos 2010, 9(2):13-20.
59. Singh MM, Biswas SK, Ashok S, Ashok KR, SINGH PP. Impaired glucose tolerance in active pulmonary tuberculosis. Ind J Tub 1984, 31(3):118-121.
60. Ikezoe J, Takeuchi N, Johkoh T, Kohno N, Tomiyama N, Kozuka T, Noma K, Ueda E. CT appearance of pulmonary tuberculosis in diabetic and immunocompromised patients: comparison with patients who had no underlying disease. AJR Am J Roentgenol 1992, 159(6):1175-1179.
61. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135(6):1924-1934. 34 e1-4.
62. Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Marjani M, Shemirani S, Pooramiri MV, Kazempour M, Farnia P, Fahimi F, Mansouri D, Masjedi M. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010, 17(1):17-22.
63. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009, 80(4):634-639.
64. Kameda K, Kawabata S, Masuda N. Follow-up study of short course chemotherapy of pulmonary tuberculosis complicated with diabetes mellitus. Kekkaku 1990, 65(12):791-803.
65. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010, 16(10):1546-1553.
66. Mboussa J, Monabeka H, Kombo M, Yokolo D, Yoka-Mbio A, Yala F. Course of pulmonary tuberculosis in diabetics. Rev Pneumol Clin 2003, 59(1):39-44.
67. Morsy AM, Zaher HH, Hassan MH, Shouman A. Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. East Mediterr Health J 2003, 9(4):689-701.
68. Tripathy SR, Kar KP, Chakraborty DC, Majumdar AK. Diabetes mellitus and pulmonary tuberculosis-a prospective study. Ind J Tub 1984, 31(3):122-125.
69. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002, 6(12):1114-1117.
70. Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002, 34(6):752-759.
71. Wang CS, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009, 137(2):203-210.
72. Young F, Critchley J, Unwin N. Diabetes & tuberculosis: a dangerous liaison & no white tiger. Indian J Med Res 2009, 130(1):1-4.
73. Zhang Q, Xiao H, Sugawara I. Tuberculosis complicated by diabetes mellitus at shanghai pulmonary hospital, china. Jpn J Infect Dis 2009, 62(5):390-391.
74. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991, 20(6):477-490.
75. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, Van Crevel R. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43(7):848-854.
76. Requena-Mendez A, Davies G, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, Moore DA. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother 2012, 56(5):2357-2363.
77. Tanrikulu AC, Hosoglu S, Ozekinci T, Abakay A, Gurkan F. Risk factors for drug resistant tuberculosis in southeast Turkey. Trop Doct 2008, 38(2):91-93.
78. Baghaei Parvaneh TP, Chitsaz E, Novin A, Kazempour M, Ali PN, Mansouri D. Risk factors associated with multidrug-resistant tuberculosis. Tanaffos 2009, 8(3):17-21.
79. Perez-Navarro LM, Fuentes-Dominguez F, Morales-Romero J, Zenteno-Cuevas R. Factors associated to pulmonary tuberculosis in patients with diabetes mellitus from Veracruz, Mexico. Gac Med Mex 2011, 147(3):219-225.
80. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008, 40(11-12):888-893.
81. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, Small PM, Pym AS. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006, 2(6):e61.
82. Jawad F, Shera AS, Memon R, Ansari G. Glucose intolerance in pulmonary tuberculosis. J Pak Med Assoc 1995, 45(9):237-238.
83. Pimazoni A. The impact of tuberculosis treatment on glycaemic control and the significant response to rosiglitazone. BMJ Case Rep 2009, doi:10.1136/bcr.09.2008.0994.
84. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-823.
85. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982, 23(1-2):56-74.
86. Takasu N, Yamada T, Miura H, Sakamoto S, Korenaga M, Nakajima K, Kanayama M. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis 1982, 125(1):23-27.
87. Waterhouse M, Wilson C, White VL, Chowdhury TA. Resolution of insulin-requiring diabetes after cessation of chemotherapy for tuberculosis. J R Soc Med 2005, 98(6):270-271.
88. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003, 42(9):819-850.
89. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999 Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161(4 Pt 2):S221-S247. (IDSA), September 1999, and the sections of this statement, This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.
90. Rose DN, Silver AL, Schechter CB. Tuberculosis chemoprophylaxis for diabetics: are the benefits of isoniazid worth the risk?. Mt Sinai J Med 1985, 52(4):253-258.
91. Pfaffenberg R, Jahler H. Isoniazid & recurrence of tuberculosis in diabetics. Z Tuberk 1958, 111(3-4):167-173.
92. Lesnichii AV, Karpina LZ. Experience with the chemoprophylaxis of pulmonary tuberculosis in diabetes mellitus patients. Probl Tuberk 1969, 47(12):1-3.
93. Harries AD, Murray MB, Jeon CY, Ottmani SE, Lonnroth K, Barreto ML, Billo N, Brostrom R, Bygbjerg IC, Fisher-Hoch S, Mori T, Ramaiya K, Roglic G, Strandgaard H, Unwin N, Viswanathan V, Whiting D, Kapur A. Defining the research agenda to reduce the joint burden of disease from diabetes mellitus and tuberculosis. Trop Med Int Health 2010, 15(6):659-663.
94. Qiao Q, Lindstrom J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 2003, 20(12):1027-1033.